secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001193125-26-208918
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RevMed Q1 net loss $453.8M, daraxonrasib shows OS 13.2 mo in pancreatic cancer
------------------------------------------------------------------------------

- Daraxonrasib Phase 3 RASolute 302: median OS 13.2 mo vs 6.7 mo chemo (HR 0.40); NDA submission planned.
- Q1 2026 net loss $453.8M vs $213.4M YoY; R&D $344M, G&A $101.3M, including $44.6M incremental SBC.
- Cash $1.9B at Mar 31, 2026; April 2026 financings raised $2.225B gross from stock and convertible notes.
- FY 2026 GAAP operating expense guidance raised to $1.7-1.8B due to ~$80M increase in non-cash SBC.
- Appointed Neil MacGregor JPAC GM, Tetsuo Endo Japan GM, Martin Voelkl Germany GM; EAP for daraxonrasib begun.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000119312526208918/0001193125-26-208918-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000119312526208918/rvmd-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-208918

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer